Yacktman Asset Management LP Sells 36,184 Shares of Kenvue Inc. (NYSE:KVUE)

Yacktman Asset Management LP cut its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 0.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,270,488 shares of the company's stock after selling 36,184 shares during the quarter. Kenvue accounts for about 2.6% of Yacktman Asset Management LP's portfolio, making the stock its 15th largest holding. Yacktman Asset Management LP owned about 0.43% of Kenvue worth $198,326,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Clarity Asset Management Inc. acquired a new position in shares of Kenvue during the 4th quarter valued at $45,000. SBI Securities Co. Ltd. bought a new position in Kenvue during the fourth quarter valued at about $46,000. Continuum Advisory LLC grew its position in Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after buying an additional 1,864 shares during the period. Rossby Financial LCC purchased a new stake in shares of Kenvue during the first quarter worth $52,000. Finally, Golden State Wealth Management LLC boosted its position in shares of Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock valued at $74,000 after acquiring an additional 2,295 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $20.71 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $22.57 and a two-hundred day moving average price of $22.32. The company has a market cap of $39.74 billion, a P/E ratio of 37.66, a PEG ratio of 3.25 and a beta of 0.83. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The company had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter in the previous year, the firm posted $0.28 EPS. Kenvue's revenue was down 3.9% on a year-over-year basis. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.96%. Kenvue's dividend payout ratio (DPR) is currently 149.09%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. UBS Group upped their target price on shares of Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Friday, May 9th. Evercore ISI began coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Barclays increased their target price on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday, May 12th. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Finally, Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.